Information  X 
Enter a valid email address

Reckitt Benckiser Gp (RB.)

  Print          Annual reports

Wednesday 07 October, 2020

Reckitt Benckiser Gp

Director Declaration

RNS Number : 4148B
Reckitt Benckiser Group PLC
07 October 2020
 

7 October 2020

 

RECKITT BENCKISER GROUP PLC

 

Director Declaration

 

 

Reckitt Benckiser Group plc announces that Sara Mathew, a Non-Executive Director of Reckitt Benckiser Group plc, has been appointed as a Director of NextGen Acquisition Corporation , with effect from 6 October 2020.

 

This notification is made in accordance with Listing Rule 9.6.14 of the FCA's Listing Rules.

 

 

 

About RB

 

RB* is driven by its purpose to protect, heal and nurture in a relentless pursuit of a cleaner, healthier world. We fight to make access to the highest-quality hygiene, wellness and nourishment a right, not a privilege, for everyone.

 

RB is proud to have a stable of trusted household brands found in households in more than 190 countries. These include Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite, Air Wick and more.  20 million RB products a day are bought by consumers globally.

 

RB's passion to put consumers and people first, to seek out new opportunities, to strive for excellence in all that we do, and to build shared success with all our partners, while doing the right thing, always is what guides the work of our 40,000+ diverse and talented colleagues worldwide. For more information visit  www.rb.com

 

*RB is the trading name of the Reckitt Benckiser group of companies

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

For further Information:
Rupert Bondy

Company Secretary

Tel +44 (0) 1753 217 800

 

John Dawson

SVP, Investor Relations

Tel. +44 (0) 1753 217 800

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNMRBJTMTAMBMM

a d v e r t i s e m e n t